迈威生物(688062.SH):9MW5211注射液临床试验申请获国家药监局批准

智通财经网
Jul 31

智通财经APP讯,迈威生物(688062.SH)发布公告,近日,公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》,9MW5211注射液用于原发性胆汁性胆管炎(PBC)适应症的临床试验申请获得批准,此前,其用于炎症性肠病(IBD)适应症的临床试验申请已分别获得国家药品监督管理局批准和FDA许可,用于多发性硬化(MS)、1型糖尿病(T1DM)和白癜风适应症的临床试验申请已获得国家药品监督管理局批准;公司亦在积极推进其他适应症临床试验申请工作。

9MW5211是公司自主研发的一种高度特异性的清除型创新抗体,针对自身免疫性疾病中由异常免疫细胞介导的关键病理机制进行精准干预。免疫细胞的异常活化及组织浸润是多种自身免疫疾病发生发展的核心驱动因素。9MW5211所靶向的分子在致病性免疫细胞表面特异性表达,是这些细胞异常活化的重要生物学标志。通过选择性识别并清除这群致病性细胞,9MW5211可有效阻断免疫级联反应,进而缓解疾病进展并改善临床症状。

更多港股重磅资讯,下载智通财经app

更多港股及海外理财资讯,请点击www.zhitongcaijing.com(搜索“智通财经”);欲加入智通港股投资群,请加智通客服微信(ztcjkf)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10